Hauptseite > Publikationsdatenbank > Kinetics of Advanced Glycation End Products Formation on Bovine Serum Albumin with Various Reducing Sugars and Dicarbonyl Compounds in Equimolar Ratios > print

001     202095
005     20210129220029.0
024 7 _ |a 10.1089/rej.2011.1284
|2 doi
024 7 _ |a pmid:22533432
|2 pmid
024 7 _ |a 1094-5458
|2 ISSN
024 7 _ |a 1549-1684
|2 ISSN
024 7 _ |a 1557-8577
|2 ISSN
024 7 _ |a 1557-8984
|2 ISSN
024 7 _ |a WOS:000303383600021
|2 WOS
037 _ _ |a FZJ-2015-04384
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Luers, Lars
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Kinetics of Advanced Glycation End Products Formation on Bovine Serum Albumin with Various Reducing Sugars and Dicarbonyl Compounds in Equimolar Ratios
260 _ _ |a Larchmont, NY
|c 2012
|b Liebert
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1435741140_1776
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
520 _ _ |a Reducing sugars and reactive dicarbonyl compounds play a major role in glycation of proteins in vivo. Glycation of proteins is the first step in of a nonenzymatic reaction, resulting in advanced glycation end products (AGEs). AGEs can inactivate proteins or modify their biological activities. Therefore, it is important to understand the mechanism of AGE formation. Here, we systematically analyzed the kinetics of AGE formation in vitro by fluorescence and absorption measurements utilizing a microplate reader system and bovine serum albumin (BSA) as a model protein. Comparing different concentrations of BSA, we applied various reducing sugars and reactive dicarbonyl compounds as AGE-inducing agents at different concentrations. In summary, this experimental setup enabled us to measure the kinetics of AGE formation in an efficient and defined way.
536 _ _ |a 452 - Structural Biology (POF2-452)
|0 G:(DE-HGF)POF2-452
|c POF2-452
|f POF II
|x 0
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de, PubMed,
650 _ 7 |a Carbohydrates
|2 NLM Chemicals
650 _ 7 |a Glycosylation End Products, Advanced
|2 NLM Chemicals
650 _ 7 |a Serum Albumin, Bovine
|2 NLM Chemicals
650 _ 7 |a Fructose
|0 30237-26-4
|2 NLM Chemicals
650 _ 7 |a Ribose
|0 681HV46001
|2 NLM Chemicals
650 _ 7 |a Arginine
|0 94ZLA3W45F
|2 NLM Chemicals
650 _ 7 |a Glucose
|0 IY9XDZ35W2
|2 NLM Chemicals
700 1 _ |a Rysiewski, K.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Dumpitak, Christian
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Birkmann, Eva
|0 P:(DE-Juel1)131992
|b 3
|e Corresponding Author
773 _ _ |a 10.1089/rej.2011.1284
|g Vol. 15, no. 2, p. 201 - 205
|0 PERI:(DE-600)2155984-3
|n 2
|p 201 - 205
|t Rejuvenation research
|v 15
|y 2012
|x 1094-5458
856 4 _ |u https://juser.fz-juelich.de/record/202095/files/rej.2011.1284.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202095/files/rej.2011.1284.gif?subformat=icon
|x icon
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202095/files/rej.2011.1284.jpg?subformat=icon-1440
|x icon-1440
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202095/files/rej.2011.1284.jpg?subformat=icon-180
|x icon-180
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202095/files/rej.2011.1284.jpg?subformat=icon-640
|x icon-640
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202095/files/rej.2011.1284.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:202095
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131992
913 2 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-552
|2 G:(DE-HGF)POF3-500
|v Engineering Cell Function
|x 0
913 1 _ |a DE-HGF
|b Schlüsseltechnologien
|1 G:(DE-HGF)POF2-450
|0 G:(DE-HGF)POF2-452
|2 G:(DE-HGF)POF2-400
|v Structural Biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
|l BioSoft
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IBI-7-20200312

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21